Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,436 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305).
Kusumoto S, Munakata W, Machida R, Terauchi T, Onaya H, Oguchi M, Iida S, Nosaka K, Suzuki Y, Harada Y, Miyazaki K, Maruta M, Fukuhara N, Toubai T, Kubota N, Ohmachi K, Saito T, Rai S, Mizuno I, Fukuhara S, Takeuchi M, Tateishi U, Maruyama D, Tsukasaki K, Nagai H. Kusumoto S, et al. Among authors: fukuhara s, fukuhara n. Cancer Sci. 2024 Oct;115(10):3384-3393. doi: 10.1111/cas.16281. Epub 2024 Jul 22. Cancer Sci. 2024. PMID: 39034771 Free PMC article.
Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H. Maeshima AM, et al. Among authors: fukuhara s. Cancer Sci. 2012 Oct;103(10):1898-904. doi: 10.1111/j.1349-7006.2012.02382.x. Epub 2012 Aug 14. Cancer Sci. 2012. PMID: 22783941 Free PMC article.
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, Shirasugi Y, Yokoyama M, Ichikawa S, Ohmachi K, Gion N, Aoi A, Tobinai K. Munakata W, et al. Among authors: fukuhara s, fukuhara n. Cancer Sci. 2019 May;110(5):1686-1694. doi: 10.1111/cas.13983. Epub 2019 Mar 28. Cancer Sci. 2019. PMID: 30815927 Free PMC article. Clinical Trial.
Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105).
Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Ohtsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H. Maruyama D, et al. Among authors: fukuhara s, fukuhara n. Cancer Sci. 2022 Sep;113(9):3267-3270. doi: 10.1111/cas.15484. Epub 2022 Jul 31. Cancer Sci. 2022. PMID: 35909244 Free PMC article. No abstract available.
Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma.
Makita S, Maruyama D, Maeshima AM, Taniguchi H, Miyamoto K, Kitahara H, Fukuhara S, Munakata W, Kobayashi Y, Itami J, Tobinai K. Makita S, et al. Among authors: fukuhara s. Int J Hematol. 2016 Aug;104(2):236-44. doi: 10.1007/s12185-016-2007-1. Epub 2016 Apr 16. Int J Hematol. 2016. PMID: 27086350
Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy.
Suzuki T, Maruyama D, Miyagi-Maeshima A, Nomoto J, Tajima K, Ito Y, Hatta S, Yuda S, Makita S, Fukuhara S, Munakata W, Suzuki T, Taniguchi H, Izutsu K, Kobayashi Y, Tobinai K. Suzuki T, et al. Among authors: fukuhara s. Cancer Med. 2021 Aug;10(15):5101-5109. doi: 10.1002/cam4.4062. Epub 2021 Jun 9. Cancer Med. 2021. PMID: 34105893 Free PMC article.
A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.
Fukushima R, Kobayashi Y, Fukuhara S, Miyamoto K, Munakata W, Maruyama D, Kim SW, Watanabe T, Taniguchi H, Maeshima A, Tobinai K. Fukushima R, et al. Among authors: fukuhara s. J Chemother. 2016 Apr;28(2):116-22. doi: 10.1080/1120009X.2015.1110898. Epub 2016 Apr 19. J Chemother. 2016. PMID: 27093518
1,436 results